For research use only. Not for therapeutic Use.
Lewis Y tetrasaccharide (Lewis Y, LeY) is a tetrasaccharide derivative form of Lewis X trisaccharide (HY-N10534). Lewis Y tetrasaccharide is an antigen associated with malignant ovarian carcinomas metastasis and poor prognosis[1][2].
Lewis Y tetrasaccharide activates FAK signaling pathway and upregulating Bcl-2/Bcl-XL expression to enhance cell adhesion mediated drug resistance (CAM-DR) in ovarian cancer cells[1].
Lewis Y tetrasaccharide results in integrin α5β1 level increase in ovarian carcinoma-derived cells exhibiting enhanced expression of LeY (RMG-1-hFUT)[2].
Lewis Y tetrasaccharide enhances the adhesive and spreading potentials mediated by the integrin-fibronectin interaction of ovarian carcinoma RMG-1 cells[2].
Anti-LeY antibodies (10 μg/mL; 37 ℃; 24 h) significantly inhibits the proliferation and adhesion ability of RMG-1-hFUT cells cultured in vivo[2].
| Catalog Number | R000165 |
| CAS Number | 82993-43-9 |
| Synonyms | N-[(2R,3R,4R,5R)-4-[(2S,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5,6-dihydroxy-1-oxo-3-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyhexan-2-yl]acetamide |
| Molecular Formula | C26H45NO19 |
| Purity | ≥95% |
| InChI | InChI=1S/C26H45NO19/c1-7-13(33)16(36)19(39)24(41-7)44-21(10(4-28)27-9(3)31)22(11(32)5-29)45-26-23(18(38)15(35)12(6-30)43-26)46-25-20(40)17(37)14(34)8(2)42-25/h4,7-8,10-26,29-30,32-40H,5-6H2,1-3H3,(H,27,31)/t7-,8-,10-,11+,12+,13+,14+,15-,16+,17+,18-,19-,20-,21+,22+,23+,24-,25-,26-/m0/s1 |
| InChIKey | APQKPNYMOAYHPL-ILVDQUQFSA-N |
| SMILES | CC1C(C(C(C(O1)OC2C(C(C(OC2OC(C(CO)O)C(C(C=O)NC(=O)C)OC3C(C(C(C(O3)C)O)O)O)CO)O)O)O)O)O |
| Reference | [1]. Yan LM, et al. Enhancement of the adhesive and spreading potentials of ovarian carcinoma RMG-1 cells due to increased expression of integrin alpha5beta1 with the Lewis Y-structure on transfection of the alpha1,2-fucosyltransferase gene. Biochimie. 2010 Jul;92(7):852-7. [2]. Yan L, et al. Lewis y enhances CAM-DR in ovarian cancer cells by activating the FAK signaling pathway and upregulating Bcl-2/Bcl-XL expression. Biochimie. 2015 Jun;113:17-25. |
